Shilpa Medicare Ltd logo

Shilpa Medicare Ltd

SHILPAMED NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹16,053 Cr
Volatility
High Risk
P/E Ratio
53.28
EBITDA
₹445 Cr
Return on Equity
9.39%
Debt to Equity
0.25
Book Value
₹132.49
52W High
₹825.4
52W Low
₹259.5

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Shilpa Medicare Ltd insights

52 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

4
  • Stock is trading at 6.11 times its book value
  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Company has a low return on equity of 5.39% over last 3 years.
  • Promoter holding has decreased over last 3 years: -9.88%

Growth Rate

Revenue Growth
18.24% ↗
Net Income Growth
210.73% ↗
Cash Flow Change
158.70% ↗
ROE
183.69% ↗
ROCE
65.20% ↗
EBITDA Margin (Avg.)
9.67% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 6d ago
AI opinion · based on fundamentals
Risk high

Shilpa Medicare Ltd trades at a market cap of ₹16,046 Cr with a PE of 53.1x and PB of 6.1x. The company has shown a sharp TTM profit growth of 117% and TTM sales growth of 28%, though its 5-year sales CAGR remains modest at 11% and 3-year average ROE stands at just 6%.

Bull Case 7
  • TTM compounded profit growth of 117% signals a strong earnings inflection after years of subdued performance
  • TTM sales growth of 28% marks a significant acceleration versus the 5-year sales CAGR of 11%
  • Stock CAGR of 85% over the past 1 year reflects strong market re-rating driven by improving fundamentals
  • Last year ROE improved to 9%, up from a 3-year average of 6% and 5-year average of 4%, indicating improving capital efficiency
  • 3-year compounded profit CAGR of 109% demonstrates sustained earnings momentum beyond a single quarter
  • Company is expected to deliver a good upcoming quarter based on available estimates
  • 3-year stock CAGR of 67% shows the re-rating has been building over multiple years, not just a short-term spike
Bear Case 8
  • PE ratio of 53.1x is elevated for a company with a 5-year sales CAGR of only 11%, implying high expectations priced in
  • Price-to-book of 6.1x is expensive relative to the 3-year average ROE of just 6%, suggesting poor value creation at current valuations
  • 5-year compounded sales growth of only 11% indicates the top-line growth engine has historically been weak
  • 3-year average ROE of 5.53% is well below cost of equity, indicating subpar shareholder returns over an extended period
  • Promoter holding has decreased by 9.88% over the last 3 years, which may signal reduced insider confidence
  • Dividend yield of just 0.12% offers negligible income support, providing no downside cushion
  • 10-year profit CAGR of only 8% shows that long-term earnings compounding has been mediocre despite the recent surge
  • 10-year stock CAGR of 11% versus 1-year CAGR of 85% highlights that most of the returns are recent and untested over full cycles

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 19h ago
Positives 3
  • Q1 net profit more than doubles Aug 5

    Consolidated net profit jumped to ₹1B from ₹470M YoY, with revenue growing to ₹4.7B from ₹3.2B and EBITDA margin improving to 29.3% from 28.51%.

  • European supply & Semaglutide filing Aug 5

    Company targets commercial supplies to a European customer in 2HFY27 and plans to complete Semaglutide DMF filing by 1HFY27, with Onco Block expansion expected by end of FY27.

  • New CEO for biologics subsidiary Aug 3

    Dr. Uday N. Harle appointed CEO of wholly owned subsidiary Shilpa Biologicals Private Limited effective August 3, 2026, signaling focus on biologics growth.

Neutral 2
  • TDS rules for Re 0.60 dividend Aug 17

    Company detailed TDS implications for FY26 final dividend of Re 0.60 per share with record date September 4, 2026, and AGM on September 11, 2026.

  • Q1FY27 earnings call hosted Aug 5

    Management hosted Q1FY27 earnings conference call on August 5, 2026, at 16:00 IST to discuss results for the quarter ended June 30, 2026.

TL;DR: Shilpa Medicare delivered a strong Q1FY27 with consolidated profit more than doubling YoY and healthy margin expansion, supported by growing revenue momentum. Strategic catalysts including European commercial supplies, Semaglutide DMF filing, and Onco Block expansion provide clear visibility for FY27. No material headwinds are evident in recent news flow. The trend is clearly improving with management expressing confidence in stronger full-year results.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
260
313
287
292
293
344
319
331
321
370
410
437
466
Expenses
214
255
222
222
222
258
239
252
231
262
296
317
330
Operating Profit
46
58
65
70
70
86
81
79
91
108
114
120
136
OPM %
18%
19%
23%
24%
24%
25%
25%
24%
28%
29%
28%
27%
29%
Other Income
2
2
2
9
10
5
2
-21
6
2
-13
45
9
Interest
18
23
26
24
24
26
12
14
19
16
11
14
12
Depreciation
27
28
27
27
27
28
29
29
29
30
30
31
35
PBT
3
9
14
28
29
37
42
15
50
64
61
120
98
Tax %
64%
83%
67%
12%
51%
51%
24%
5%
5%
32%
27%
10%
-3%
Net Profit
1
2
5
24
14
18
32
15
47
44
45
108
101
EPS in Rs
0.07
0.09
0.26
1.41
0.72
0.92
1.62
0.74
2.4
2.25
2.28
5.51
5.16
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
614
719
779
789
733
908
899
1,141
1,046
1,146
1,281
1,535
1,683
Expenses
485
566
614
634
585
688
718
940
947
907
962
1,100
1,204
Operating Profit
129
153
165
155
148
219
181
202
99
239
319
435
479
OPM %
21%
21%
21%
20%
20%
24%
20%
18%
9%
21%
25%
28%
28%
Other Income
5
5
15
22
33
17
90
21
17
15
-8
39
43
Interest
4
7
3
3
4
5
22
41
59
92
76
59
52
Depreciation
21
29
31
37
42
44
54
80
96
108
113
120
126
PBT
108
122
146
137
136
188
195
102
-38
54
122
295
344
Tax %
33%
19%
29%
25%
19%
18%
25%
41%
-19%
41%
36%
18%
—
Net Profit
73
99
104
103
110
155
146
61
-31
32
78
243
297
EPS in Rs
4.78
6.73
6.71
6.45
6.88
9.57
9.06
3.49
-1.87
1.84
4
12.44
15.2
Div. Payout %
6%
4%
4%
5%
7%
6%
6%
16%
0%
0%
12%
5%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
8
8
8
8
8
8
9
9
9
10
20
Reserves
539
639
979
1,077
1,189
1,321
1,471
1,814
1,775
1,800
2,353
2,572
Borrowings
189
221
241
191
194
390
846
683
798
937
588
660
Other Liabilities
169
194
244
223
218
270
308
370
323
347
360
455
Total Liabilities
905
1,062
1,472
1,499
1,610
1,989
2,632
2,876
2,904
3,093
3,311
3,706
Fixed Assets
316
580
492
534
558
650
1,111
1,342
1,368
1,385
1,418
1,593
CWIP
222
95
141
210
429
666
541
506
655
719
822
884
Investments
66
53
253
140
2
10
21
34
43
40
35
58
Other Assets
301
334
587
615
621
662
959
993
838
950
1,037
1,170
Total Assets
905
1,062
1,472
1,499
1,610
1,989
2,632
2,876
2,904
3,093
3,311
3,706
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
69
129
37
45
147
124
47
105
180
137
132
342
Investing
-196
-106
-257
-10
-196
-290
-404
-286
-232
-171
-198
-339
Financing
136
-20
313
-61
10
176
436
83
46
47
63
14
Net Cash Flow
9
3
93
-26
-39
10
79
-98
-7
13
-3
17
Free Cash Flow
-74
12
-79
-92
-151
-220
-302
-226
-46
-48
-111
-28
CFO/OP
73
103
43
55
123
76
52
69
215
74
56
93
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
48
43
80
102
101
99
88
124
113
125
126
123
Inventory Days
147
161
187
194
266
298
427
338
280
309
309
291
Days Payable
85
101
110
106
115
122
91
139
125
156
93
113
Cash Conversion Cycle
111
104
157
189
253
275
425
323
268
278
342
301
Working Capital Days
33
27
79
98
98
68
72
77
-13
48
80
51
ROCE %
18%
16%
14%
10%
9%
12%
8%
6%
1%
5%
8%
11%

Shareholding Pattern

As of Jun 2026
Promoters 40.13%
Public 27.67%
Others 12.76%
FIIs 11.38%
DIIs 8.05%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Nov 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Apr 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
53.25%
53.25%
53.25%
50.01%
50.01%
50.01%
50.01%
50.01%
50.01%
50.01%
50.01%
50.01%
50.01%
50.01%
44.39%
44.39%
44.33%
44.23%
44.23%
44.23%
44.23%
40.13%
40.13%
40.13%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
8.60%
8.52%
0.00%
0.00%
9.08%
9.58%
9.90%
10.97%
11.20%
10.92%
10.97%
11.08%
11.38%
DIIs
2.95%
2.05%
2.29%
2.15%
2.12%
1.01%
1.01%
1.01%
0.61%
0.54%
0.00%
0.41%
0.06%
1.59%
6.13%
7.61%
8.18%
8.27%
7.55%
7.46%
7.67%
8.33%
8.58%
8.05%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
16.80%
17.89%
19.49%
18.23%
18.57%
20.12%
20.51%
18.95%
21.85%
24.05%
26.82%
25.40%
25.45%
27.64%
24.54%
24.69%
23.94%
24.40%
24.43%
23.21%
23.34%
27.80%
27.70%
27.67%
Others
27.01%
26.81%
24.97%
29.61%
29.31%
28.87%
28.47%
30.03%
27.52%
25.40%
23.17%
15.59%
15.96%
20.75%
24.94%
14.23%
13.96%
13.21%
12.83%
13.90%
13.84%
12.76%
12.51%
12.76%
No. of Shareholders
51,277
53,220
46,540
40,592
39,565
39,724
39,097
41,579
46,143
46,869
50,434
44,094
43,630
44,793
44,809
41,072
42,784
49,034
50,108
48,636
52,065
53,799
53,410
60,926

Documents

1
Concall - Feb 2020 Feb 2020
2
Concall - Jun 2020 Jun 2020
3
Concall - Jun 2020 Jun 2020
4
Concall - Aug 2020 Aug 2020
5
Concall - Nov 2020 Nov 2020

Frequently Asked Questions about Shilpa Medicare Ltd

What does Shilpa Medicare Ltd do?
Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML a...
Where is Shilpa Medicare Ltd (SHILPAMED) listed?
Shilpa Medicare Ltd is listed on the Indian stock exchanges. It is listed on NSE: SHILPAMED and BSE: 530549. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Shilpa Medicare Ltd belong to?
Shilpa Medicare Ltd operates in the Healthcare sector within the Pharmaceuticals & Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Shilpa Medicare Ltd?
Shilpa Medicare Ltd has a market capitalisation of approximately ₹16053.36 Cr. Based on this, it is classified as a Mid Cap stock.
What is the PE ratio of Shilpa Medicare Ltd?
The Price-to-Earnings (PE) ratio of Shilpa Medicare Ltd is 53.28. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Shilpa Medicare Ltd?
Over the past 52 weeks, Shilpa Medicare Ltd has traded between a low of ₹259.5 and a high of ₹825.4. This range helps investors understand the stock's price volatility and recent trading levels.
Does Shilpa Medicare Ltd pay dividends?
Yes, Shilpa Medicare Ltd has a dividend yield of 0.07%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Shilpa Medicare Ltd?
Shilpa Medicare Ltd has a Return on Equity (ROE) of 9.39%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Shilpa Medicare Ltd on Tapetide?
On Tapetide, you can view Shilpa Medicare Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Shilpa Medicare Incorporated in 1987 manufactures niche APIs, intermediates, and formulations and also undertakes contract research and manufacturing service for some of its customers. The company’s formulation products consist of 16 injectable dosage forms, 19 oral solid dosage forms under SML and 13 formulations under SML’s wholly owned subsidiary Shilpa Therapeutics.[1]

Website vbshilpa.com
CEO Mr. Vishnukanth Chaturbhuj Bhutada B. Pharm
Employees 998
Listed 2009-12-03
Face Value ₹ 1
Issued Size 19,55,81,816

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List